As of September 30, 2026, Agios Pharmaceuticals, Inc. carries a market capitalization of 1.77B, placing it among publicly traded companies globally. Its enterprise value stands at 1.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.77B |
| Enterprise Value | 1.24B |
Agios Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for February 25, 2027.
| Earnings Date | 2/25/2027 |
As of September 30, 2026, Agios Pharmaceuticals, Inc. has 59.78M shares outstanding.
| Shares Outstanding | 59.78M |
These figures are as of September 30, 2026. The price-to-sales ratio is 14.07, and the price-to-book ratio stands at 2.05.
| PS Ratio | 14.07 |
| PB Ratio | 2.05 |
| P/TBV Ratio | 2.05 |
| P/FCF Ratio | -5.90 |
| P/OCF Ratio | -5.98 |
These figures are as of September 30, 2026. The EV/Sales ratio of 9.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.24B versus a market cap of 1.77B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 9.95 |
As of September 30, 2026, Agios Pharmaceuticals, Inc. maintains a current ratio of 9.69, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.69 |
| Quick Ratio | 8.54 |
| Debt / Equity | 2.71 |
| Debt / EBITDA | -0.06 |
Over the twelve months ended September 30, 2026, Agios Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -32.95, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -30.44, reflecting losses generated across the asset base. The company generates approximately 230,121.81 in revenue per employee across its workforce of 540.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.25 indicates how many times Agios Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -32.95 |
| Return on Assets (ROA) | -30.44 |
| Revenue Per Employee | 230,121.81 |
| Employee Count | 540.00 |
| Inventory Turnover | 0.25 |
Over the twelve months ended September 30, 2026, Agios Pharmaceuticals, Inc. recorded an income tax benefit of -896,416.80 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -329.90M and -329.01M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -896,416.80 |
As of the close on November 17, 2026, Agios Pharmaceuticals, Inc.'s stock has declined approximately 30.41% over the past 52 weeks. The 50-day moving average sits at 29.30, while the 200-day moving average is 27.78.
| 52-Week Price Change | -30.41% |
| 50-Day Moving Average | 29.30 |
| 200-Day Moving Average | 27.78 |
Over the twelve months ended September 30, 2026, Agios Pharmaceuticals, Inc. generated 124.27M in revenue and converted that into -329.01M in net income, yielding earnings per share of -5.57. EBITDA reached -365.17M, while operating income came in at -369.96M.
| Revenue | 124.27M |
| Gross Profit | 116.57M |
| Operating Income | -369.96M |
| Pretax Income | -329.90M |
| Net Income | -329.01M |
| EBITDA | -365.17M |
| EBIT | -369.96M |
| Earnings Per Share (EPS) | -5.57 |
As of September 30, 2026, Agios Pharmaceuticals, Inc. holds 555.86M in cash and equivalents against 23.41M in total debt, resulting in a net debt position of -113.42M. Total book value stands at 864.07M, with working capital of 595.12M providing operational flexibility.
| Cash & Cash Equivalents | 555.86M |
| Total Debt | 23.41M |
| Net Debt | -113.42M |
| Equity (Book Value) | 864.07M |
| Book Value Per Share | 14.45 |
| Working Capital | 595.12M |
Agios Pharmaceuticals, Inc. produced -292.64M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -3.78M in capital expenditures, free cash flow totaled -296.42M - equivalent to -5.02 per share.
| Operating Cash Flow | -292.64M |
| Capital Expenditures | -3.78M |
| Free Cash Flow | -296.42M |
| FCF Per Share | -5.02 |
Over the twelve months ended September 30, 2026, Agios Pharmaceuticals, Inc. posted a gross margin of 93.81, reflecting its pricing power and cost economics. The operating margin of -297.72 and net profit margin of -264.76 provide insight into operational efficiency.
| Gross Margin | 93.81 |
| Operating Margin | -297.72 |
| Pretax Margin | -265.48 |
| Profit Margin | -264.76 |
| EBITDA Margin | -293.86 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -16.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.60, meaning Agios Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.60 |
| FCF Yield | -16.95 |
As of September 30, 2026, Agios Pharmaceuticals, Inc. has an Altman Z-Score of 12.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 12.71 |